Solventum Corporation
Solventum Corporation SOLV Peers
See (SOLV) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SOLV | $74.59 | -0.48% | 12.9B | 34.38 | $2.17 | N/A |
| HCA | $380.75 | +1.75% | 90.9B | 16.57 | $22.80 | +0.73% |
| BKDT | $77.60 | +0.00% | 16.6B | N/A | N/A | N/A |
| FMS | $28.04 | +1.12% | 16.5B | 23.22 | $1.21 | +2.80% |
| THC | $174.00 | +2.95% | 16B | 11.06 | $15.60 | N/A |
| EHC | $121.60 | +0.77% | 12.2B | 25.01 | $4.86 | +0.55% |
| UHS | $179.52 | +2.18% | 11.4B | 9.96 | $17.81 | +0.45% |
| DVA | $142.23 | +1.33% | 10.7B | 14.00 | $10.08 | N/A |
| OSH | $39.00 | +0.08% | 9.5B | -17.65 | -$2.21 | N/A |
| ENSG | $154.75 | +1.46% | 8.8B | 29.02 | $5.30 | +0.16% |
Stock Comparison
SOLV vs HCA Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, HCA has a market cap of 90.9B. Regarding current trading prices, SOLV is priced at $74.59, while HCA trades at $380.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas HCA's P/E ratio is 16.57. In terms of profitability, SOLV's ROE is +0.12%, compared to HCA's ROE of -2.36%. Regarding short-term risk, SOLV is more volatile compared to HCA. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.
SOLV vs BKDT Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, BKDT has a market cap of 16.6B. Regarding current trading prices, SOLV is priced at $74.59, while BKDT trades at $77.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas BKDT's P/E ratio is N/A. In terms of profitability, SOLV's ROE is +0.12%, compared to BKDT's ROE of -0.96%. Regarding short-term risk, SOLV is more volatile compared to BKDT. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.
SOLV vs FMS Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, FMS has a market cap of 16.5B. Regarding current trading prices, SOLV is priced at $74.59, while FMS trades at $28.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas FMS's P/E ratio is 23.22. In terms of profitability, SOLV's ROE is +0.12%, compared to FMS's ROE of +0.04%. Regarding short-term risk, SOLV is less volatile compared to FMS. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs THC Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, THC has a market cap of 16B. Regarding current trading prices, SOLV is priced at $74.59, while THC trades at $174.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas THC's P/E ratio is 11.06. In terms of profitability, SOLV's ROE is +0.12%, compared to THC's ROE of +0.37%. Regarding short-term risk, SOLV is more volatile compared to THC. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.
SOLV vs EHC Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, EHC has a market cap of 12.2B. Regarding current trading prices, SOLV is priced at $74.59, while EHC trades at $121.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas EHC's P/E ratio is 25.01. In terms of profitability, SOLV's ROE is +0.12%, compared to EHC's ROE of +0.25%. Regarding short-term risk, SOLV is more volatile compared to EHC. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.
SOLV vs UHS Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, UHS has a market cap of 11.4B. Regarding current trading prices, SOLV is priced at $74.59, while UHS trades at $179.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas UHS's P/E ratio is 9.96. In terms of profitability, SOLV's ROE is +0.12%, compared to UHS's ROE of +0.18%. Regarding short-term risk, SOLV is less volatile compared to UHS. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs DVA Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, DVA has a market cap of 10.7B. Regarding current trading prices, SOLV is priced at $74.59, while DVA trades at $142.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas DVA's P/E ratio is 14.00. In terms of profitability, SOLV's ROE is +0.12%, compared to DVA's ROE of +3.94%. Regarding short-term risk, SOLV is less volatile compared to DVA. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs OSH Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, OSH has a market cap of 9.5B. Regarding current trading prices, SOLV is priced at $74.59, while OSH trades at $39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas OSH's P/E ratio is -17.65. In terms of profitability, SOLV's ROE is +0.12%, compared to OSH's ROE of +4.64%. Regarding short-term risk, SOLV is more volatile compared to OSH. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.
SOLV vs ENSG Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, ENSG has a market cap of 8.8B. Regarding current trading prices, SOLV is priced at $74.59, while ENSG trades at $154.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas ENSG's P/E ratio is 29.02. In terms of profitability, SOLV's ROE is +0.12%, compared to ENSG's ROE of +0.17%. Regarding short-term risk, SOLV is more volatile compared to ENSG. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.
SOLV vs CHE Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, CHE has a market cap of 8.1B. Regarding current trading prices, SOLV is priced at $74.59, while CHE trades at $557.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas CHE's P/E ratio is 27.13. In terms of profitability, SOLV's ROE is +0.12%, compared to CHE's ROE of +0.26%. Regarding short-term risk, SOLV is more volatile compared to CHE. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.
SOLV vs LHCG Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, LHCG has a market cap of 5.3B. Regarding current trading prices, SOLV is priced at $74.59, while LHCG trades at $169.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas LHCG's P/E ratio is 82.83. In terms of profitability, SOLV's ROE is +0.12%, compared to LHCG's ROE of +0.04%. Regarding short-term risk, SOLV is more volatile compared to LHCG. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.
SOLV vs OPCH Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, OPCH has a market cap of 5.2B. Regarding current trading prices, SOLV is priced at $74.59, while OPCH trades at $32.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas OPCH's P/E ratio is 25.60. In terms of profitability, SOLV's ROE is +0.12%, compared to OPCH's ROE of +0.15%. Regarding short-term risk, SOLV is less volatile compared to OPCH. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs AMED Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, AMED has a market cap of 3.2B. Regarding current trading prices, SOLV is priced at $74.59, while AMED trades at $97.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas AMED's P/E ratio is 36.17. In terms of profitability, SOLV's ROE is +0.12%, compared to AMED's ROE of +0.10%. Regarding short-term risk, SOLV is more volatile compared to AMED. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.
SOLV vs SGRY Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, SGRY has a market cap of 2.8B. Regarding current trading prices, SOLV is priced at $74.59, while SGRY trades at $21.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas SGRY's P/E ratio is -14.18. In terms of profitability, SOLV's ROE is +0.12%, compared to SGRY's ROE of -0.10%. Regarding short-term risk, SOLV is more volatile compared to SGRY. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.
SOLV vs ADUS Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, ADUS has a market cap of 2.1B. Regarding current trading prices, SOLV is priced at $74.59, while ADUS trades at $115.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas ADUS's P/E ratio is 26.12. In terms of profitability, SOLV's ROE is +0.12%, compared to ADUS's ROE of +0.08%. Regarding short-term risk, SOLV is more volatile compared to ADUS. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.
SOLV vs ACHC Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, ACHC has a market cap of 2B. Regarding current trading prices, SOLV is priced at $74.59, while ACHC trades at $21.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas ACHC's P/E ratio is 10.81. In terms of profitability, SOLV's ROE is +0.12%, compared to ACHC's ROE of +0.06%. Regarding short-term risk, SOLV is less volatile compared to ACHC. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs LFST Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, LFST has a market cap of 2B. Regarding current trading prices, SOLV is priced at $74.59, while LFST trades at $5.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas LFST's P/E ratio is -56.44. In terms of profitability, SOLV's ROE is +0.12%, compared to LFST's ROE of -0.02%. Regarding short-term risk, SOLV is less volatile compared to LFST. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs SEM Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, SEM has a market cap of 1.9B. Regarding current trading prices, SOLV is priced at $74.59, while SEM trades at $15.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas SEM's P/E ratio is 24.24. In terms of profitability, SOLV's ROE is +0.12%, compared to SEM's ROE of +0.10%. Regarding short-term risk, SOLV is less volatile compared to SEM. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs ARDT Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, ARDT has a market cap of 1.9B. Regarding current trading prices, SOLV is priced at $74.59, while ARDT trades at $13.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas ARDT's P/E ratio is 7.92. In terms of profitability, SOLV's ROE is +0.12%, compared to ARDT's ROE of +0.24%. Regarding short-term risk, SOLV is less volatile compared to ARDT. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs AMEH Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, AMEH has a market cap of 1.8B. Regarding current trading prices, SOLV is priced at $74.59, while AMEH trades at $40.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas AMEH's P/E ratio is 39.25. In terms of profitability, SOLV's ROE is +0.12%, compared to AMEH's ROE of +0.07%. Regarding short-term risk, SOLV is less volatile compared to AMEH. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs NHC Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, NHC has a market cap of 1.7B. Regarding current trading prices, SOLV is priced at $74.59, while NHC trades at $109.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas NHC's P/E ratio is 15.76. In terms of profitability, SOLV's ROE is +0.12%, compared to NHC's ROE of +0.11%. Regarding short-term risk, SOLV is more volatile compared to NHC. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.
SOLV vs BKD Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, BKD has a market cap of 1.6B. Regarding current trading prices, SOLV is priced at $74.59, while BKD trades at $6.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas BKD's P/E ratio is -6.72. In terms of profitability, SOLV's ROE is +0.12%, compared to BKD's ROE of -0.96%. Regarding short-term risk, SOLV is more volatile compared to BKD. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.
SOLV vs ASTH Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, ASTH has a market cap of 1.2B. Regarding current trading prices, SOLV is priced at $74.59, while ASTH trades at $24.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas ASTH's P/E ratio is 33.86. In terms of profitability, SOLV's ROE is +0.12%, compared to ASTH's ROE of +0.07%. Regarding short-term risk, SOLV is more volatile compared to ASTH. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.
SOLV vs USPH Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, USPH has a market cap of 1.2B. Regarding current trading prices, SOLV is priced at $74.59, while USPH trades at $78.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas USPH's P/E ratio is 36.15. In terms of profitability, SOLV's ROE is +0.12%, compared to USPH's ROE of +0.06%. Regarding short-term risk, SOLV is less volatile compared to USPH. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs MD Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, MD has a market cap of 1.2B. Regarding current trading prices, SOLV is priced at $74.59, while MD trades at $13.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas MD's P/E ratio is -13.62. In terms of profitability, SOLV's ROE is +0.12%, compared to MD's ROE of -0.11%. Regarding short-term risk, SOLV is less volatile compared to MD. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs HCSG Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, HCSG has a market cap of 1.1B. Regarding current trading prices, SOLV is priced at $74.59, while HCSG trades at $14.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas HCSG's P/E ratio is 27.07. In terms of profitability, SOLV's ROE is +0.12%, compared to HCSG's ROE of +0.08%. Regarding short-term risk, SOLV is less volatile compared to HCSG. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs PNTG Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, PNTG has a market cap of 1B. Regarding current trading prices, SOLV is priced at $74.59, while PNTG trades at $29.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas PNTG's P/E ratio is 38.28. In terms of profitability, SOLV's ROE is +0.12%, compared to PNTG's ROE of +0.11%. Regarding short-term risk, SOLV is less volatile compared to PNTG. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs AGL Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, AGL has a market cap of 956.2M. Regarding current trading prices, SOLV is priced at $74.59, while AGL trades at $2.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas AGL's P/E ratio is -3.73. In terms of profitability, SOLV's ROE is +0.12%, compared to AGL's ROE of -0.44%. Regarding short-term risk, SOLV is less volatile compared to AGL. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs AVAH Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, AVAH has a market cap of 939.4M. Regarding current trading prices, SOLV is priced at $74.59, while AVAH trades at $4.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas AVAH's P/E ratio is 160.50. In terms of profitability, SOLV's ROE is +0.12%, compared to AVAH's ROE of -0.12%. Regarding short-term risk, SOLV is more volatile compared to AVAH. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.
SOLV vs AMN Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, AMN has a market cap of 805.1M. Regarding current trading prices, SOLV is priced at $74.59, while AMN trades at $21.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas AMN's P/E ratio is -4.86. In terms of profitability, SOLV's ROE is +0.12%, compared to AMN's ROE of -0.21%. Regarding short-term risk, SOLV is more volatile compared to AMN. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.
SOLV vs INNV Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, INNV has a market cap of 534.7M. Regarding current trading prices, SOLV is priced at $74.59, while INNV trades at $3.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas INNV's P/E ratio is -16.50. In terms of profitability, SOLV's ROE is +0.12%, compared to INNV's ROE of -0.12%. Regarding short-term risk, SOLV is less volatile compared to INNV. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs CYH Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, CYH has a market cap of 488.3M. Regarding current trading prices, SOLV is priced at $74.59, while CYH trades at $3.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas CYH's P/E ratio is -0.95. In terms of profitability, SOLV's ROE is +0.12%, compared to CYH's ROE of +0.30%. Regarding short-term risk, SOLV is less volatile compared to CYH. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs EHAB Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, EHAB has a market cap of 482.6M. Regarding current trading prices, SOLV is priced at $74.59, while EHAB trades at $9.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas EHAB's P/E ratio is -3.44. In terms of profitability, SOLV's ROE is +0.12%, compared to EHAB's ROE of -0.31%. Regarding short-term risk, SOLV is more volatile compared to EHAB. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.
SOLV vs TALKW Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, TALKW has a market cap of 481.6M. Regarding current trading prices, SOLV is priced at $74.59, while TALKW trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas TALKW's P/E ratio is N/A. In terms of profitability, SOLV's ROE is +0.12%, compared to TALKW's ROE of -0.04%. Regarding short-term risk, SOLV is more volatile compared to TALKW. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.
SOLV vs AUNA Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, AUNA has a market cap of 471.5M. Regarding current trading prices, SOLV is priced at $74.59, while AUNA trades at $6.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas AUNA's P/E ratio is 10.11. In terms of profitability, SOLV's ROE is +0.12%, compared to AUNA's ROE of +0.07%. Regarding short-term risk, SOLV is less volatile compared to AUNA. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs SNDA Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, SNDA has a market cap of 460.3M. Regarding current trading prices, SOLV is priced at $74.59, while SNDA trades at $24.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas SNDA's P/E ratio is -6.72. In terms of profitability, SOLV's ROE is +0.12%, compared to SNDA's ROE of -0.53%. Regarding short-term risk, SOLV is less volatile compared to SNDA. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs TALK Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, TALK has a market cap of 460.1M. Regarding current trading prices, SOLV is priced at $74.59, while TALK trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas TALK's P/E ratio is 137.50. In terms of profitability, SOLV's ROE is +0.12%, compared to TALK's ROE of -0.04%. Regarding short-term risk, SOLV is less volatile compared to TALK. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs CCRN Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, CCRN has a market cap of 429.8M. Regarding current trading prices, SOLV is priced at $74.59, while CCRN trades at $13.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas CCRN's P/E ratio is -24.28. In terms of profitability, SOLV's ROE is +0.12%, compared to CCRN's ROE of -0.04%. Regarding short-term risk, SOLV is less volatile compared to CCRN. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs AONC Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, AONC has a market cap of 392.6M. Regarding current trading prices, SOLV is priced at $74.59, while AONC trades at $13.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas AONC's P/E ratio is -15.12. In terms of profitability, SOLV's ROE is +0.12%, compared to AONC's ROE of +0.25%. Regarding short-term risk, SOLV is less volatile compared to AONC. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs AIRS Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, AIRS has a market cap of 296.2M. Regarding current trading prices, SOLV is priced at $74.59, while AIRS trades at $4.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas AIRS's P/E ratio is -16.36. In terms of profitability, SOLV's ROE is +0.12%, compared to AIRS's ROE of -0.21%. Regarding short-term risk, SOLV is less volatile compared to AIRS. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs CMPS Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, CMPS has a market cap of 247M. Regarding current trading prices, SOLV is priced at $74.59, while CMPS trades at $2.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas CMPS's P/E ratio is -1.34. In terms of profitability, SOLV's ROE is +0.12%, compared to CMPS's ROE of -0.72%. Regarding short-term risk, SOLV is less volatile compared to CMPS. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs TOIIW Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, TOIIW has a market cap of 233.4M. Regarding current trading prices, SOLV is priced at $74.59, while TOIIW trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas TOIIW's P/E ratio is N/A. In terms of profitability, SOLV's ROE is +0.12%, compared to TOIIW's ROE of -4.83%. Regarding short-term risk, SOLV is less volatile compared to TOIIW. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs CSU Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, CSU has a market cap of 223.7M. Regarding current trading prices, SOLV is priced at $74.59, while CSU trades at $33.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas CSU's P/E ratio is 0.67. In terms of profitability, SOLV's ROE is +0.12%, compared to CSU's ROE of +2.23%. Regarding short-term risk, SOLV is less volatile compared to CSU. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs TOI Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, TOI has a market cap of 205.9M. Regarding current trading prices, SOLV is priced at $74.59, while TOI trades at $2.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas TOI's P/E ratio is -3.20. In terms of profitability, SOLV's ROE is +0.12%, compared to TOI's ROE of -4.83%. Regarding short-term risk, SOLV is less volatile compared to TOI. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs JYNT Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, JYNT has a market cap of 177.7M. Regarding current trading prices, SOLV is priced at $74.59, while JYNT trades at $11.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas JYNT's P/E ratio is -116.10. In terms of profitability, SOLV's ROE is +0.12%, compared to JYNT's ROE of -0.43%. Regarding short-term risk, SOLV is less volatile compared to JYNT. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs DCGO Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, DCGO has a market cap of 167.5M. Regarding current trading prices, SOLV is priced at $74.59, while DCGO trades at $1.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas DCGO's P/E ratio is -169.00. In terms of profitability, SOLV's ROE is +0.12%, compared to DCGO's ROE of -0.00%. Regarding short-term risk, SOLV is less volatile compared to DCGO. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs BTMD Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, BTMD has a market cap of 163.9M. Regarding current trading prices, SOLV is priced at $74.59, while BTMD trades at $4.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas BTMD's P/E ratio is 7.38. In terms of profitability, SOLV's ROE is +0.12%, compared to BTMD's ROE of -0.19%. Regarding short-term risk, SOLV is less volatile compared to BTMD. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs FVE Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, FVE has a market cap of 98.4M. Regarding current trading prices, SOLV is priced at $74.59, while FVE trades at $2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas FVE's P/E ratio is -5.64. In terms of profitability, SOLV's ROE is +0.12%, compared to FVE's ROE of -0.15%. Regarding short-term risk, SOLV is less volatile compared to FVE. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs KDLYW Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, KDLYW has a market cap of 96.5M. Regarding current trading prices, SOLV is priced at $74.59, while KDLYW trades at $18.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas KDLYW's P/E ratio is N/A. In terms of profitability, SOLV's ROE is +0.12%, compared to KDLYW's ROE of -1.46%. Regarding short-term risk, SOLV is less volatile compared to KDLYW. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs MODV Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, MODV has a market cap of 50.5M. Regarding current trading prices, SOLV is priced at $74.59, while MODV trades at $3.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas MODV's P/E ratio is -0.22. In terms of profitability, SOLV's ROE is +0.12%, compared to MODV's ROE of +6.87%. Regarding short-term risk, SOLV is less volatile compared to MODV. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs ALR Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, ALR has a market cap of 44.2M. Regarding current trading prices, SOLV is priced at $74.59, while ALR trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas ALR's P/E ratio is -1.11. In terms of profitability, SOLV's ROE is +0.12%, compared to ALR's ROE of -0.15%. Regarding short-term risk, SOLV is less volatile compared to ALR. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs CCEL Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, CCEL has a market cap of 42.1M. Regarding current trading prices, SOLV is priced at $74.59, while CCEL trades at $5.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas CCEL's P/E ratio is 520.50. In terms of profitability, SOLV's ROE is +0.12%, compared to CCEL's ROE of -0.01%. Regarding short-term risk, SOLV is less volatile compared to CCEL. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs IMAC Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, IMAC has a market cap of 33.1M. Regarding current trading prices, SOLV is priced at $74.59, while IMAC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas IMAC's P/E ratio is -2.27. In terms of profitability, SOLV's ROE is +0.12%, compared to IMAC's ROE of +2.46%. Regarding short-term risk, SOLV is less volatile compared to IMAC. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs PIII Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, PIII has a market cap of 20.2M. Regarding current trading prices, SOLV is priced at $74.59, while PIII trades at $6.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas PIII's P/E ratio is -0.12. In terms of profitability, SOLV's ROE is +0.12%, compared to PIII's ROE of -1.29%. Regarding short-term risk, SOLV is less volatile compared to PIII. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs AIH Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, AIH has a market cap of 15.9M. Regarding current trading prices, SOLV is priced at $74.59, while AIH trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas AIH's P/E ratio is -2.78. In terms of profitability, SOLV's ROE is +0.12%, compared to AIH's ROE of +1.16%. Regarding short-term risk, SOLV is less volatile compared to AIH. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs AMS Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, AMS has a market cap of 15.5M. Regarding current trading prices, SOLV is priced at $74.59, while AMS trades at $2.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas AMS's P/E ratio is 11.42. In terms of profitability, SOLV's ROE is +0.12%, compared to AMS's ROE of +0.06%. Regarding short-term risk, SOLV is less volatile compared to AMS. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs CANO Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, CANO has a market cap of 12.4M. Regarding current trading prices, SOLV is priced at $74.59, while CANO trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas CANO's P/E ratio is -0.01. In terms of profitability, SOLV's ROE is +0.12%, compared to CANO's ROE of -1.49%. Regarding short-term risk, SOLV is less volatile compared to CANO. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs FTRP Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, FTRP has a market cap of 9.8M. Regarding current trading prices, SOLV is priced at $74.59, while FTRP trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas FTRP's P/E ratio is -1.22. In terms of profitability, SOLV's ROE is +0.12%, compared to FTRP's ROE of -0.62%. Regarding short-term risk, SOLV is less volatile compared to FTRP. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs GBNH Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, GBNH has a market cap of 5.5M. Regarding current trading prices, SOLV is priced at $74.59, while GBNH trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas GBNH's P/E ratio is -0.06. In terms of profitability, SOLV's ROE is +0.12%, compared to GBNH's ROE of +15.74%. Regarding short-term risk, SOLV is less volatile compared to GBNH. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs RHE Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, RHE has a market cap of 5.2M. Regarding current trading prices, SOLV is priced at $74.59, while RHE trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas RHE's P/E ratio is -1.79. In terms of profitability, SOLV's ROE is +0.12%, compared to RHE's ROE of +1.52%. Regarding short-term risk, SOLV is less volatile compared to RHE. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs MNDR Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, MNDR has a market cap of 4.9M. Regarding current trading prices, SOLV is priced at $74.59, while MNDR trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas MNDR's P/E ratio is -0.16. In terms of profitability, SOLV's ROE is +0.12%, compared to MNDR's ROE of -5.70%. Regarding short-term risk, SOLV is less volatile compared to MNDR. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs ATIP Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, ATIP has a market cap of 3.8M. Regarding current trading prices, SOLV is priced at $74.59, while ATIP trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas ATIP's P/E ratio is -0.04. In terms of profitability, SOLV's ROE is +0.12%, compared to ATIP's ROE of +1.77%. Regarding short-term risk, SOLV is more volatile compared to ATIP. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.
SOLV vs IMACW Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, IMACW has a market cap of 1.7M. Regarding current trading prices, SOLV is priced at $74.59, while IMACW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas IMACW's P/E ratio is N/A. In terms of profitability, SOLV's ROE is +0.12%, compared to IMACW's ROE of +2.46%. Regarding short-term risk, SOLV is less volatile compared to IMACW. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs SYRA Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, SYRA has a market cap of 1.2M. Regarding current trading prices, SOLV is priced at $74.59, while SYRA trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas SYRA's P/E ratio is -0.31. In terms of profitability, SOLV's ROE is +0.12%, compared to SYRA's ROE of -1.04%. Regarding short-term risk, SOLV is less volatile compared to SYRA. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs NIVFW Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, NIVFW has a market cap of 1.1M. Regarding current trading prices, SOLV is priced at $74.59, while NIVFW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas NIVFW's P/E ratio is N/A. In terms of profitability, SOLV's ROE is +0.12%, compared to NIVFW's ROE of -0.39%. Regarding short-term risk, SOLV is less volatile compared to NIVFW. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs CCM Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, CCM has a market cap of 804.8K. Regarding current trading prices, SOLV is priced at $74.59, while CCM trades at $5.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas CCM's P/E ratio is -0.56. In terms of profitability, SOLV's ROE is +0.12%, compared to CCM's ROE of +0.13%. Regarding short-term risk, SOLV is less volatile compared to CCM. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs RHE-PA Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, RHE-PA has a market cap of 674.5K. Regarding current trading prices, SOLV is priced at $74.59, while RHE-PA trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas RHE-PA's P/E ratio is -0.09. In terms of profitability, SOLV's ROE is +0.12%, compared to RHE-PA's ROE of +1.52%. Regarding short-term risk, SOLV is less volatile compared to RHE-PA. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs BACK Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, BACK has a market cap of 189.6K. Regarding current trading prices, SOLV is priced at $74.59, while BACK trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas BACK's P/E ratio is -0.01. In terms of profitability, SOLV's ROE is +0.12%, compared to BACK's ROE of +2.46%. Regarding short-term risk, SOLV is less volatile compared to BACK. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs IONM Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, IONM has a market cap of 149.8K. Regarding current trading prices, SOLV is priced at $74.59, while IONM trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas IONM's P/E ratio is N/A. In terms of profitability, SOLV's ROE is +0.12%, compared to IONM's ROE of +0.75%. Regarding short-term risk, SOLV is less volatile compared to IONM. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs NVOS Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, NVOS has a market cap of 78.9K. Regarding current trading prices, SOLV is priced at $74.59, while NVOS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas NVOS's P/E ratio is N/A. In terms of profitability, SOLV's ROE is +0.12%, compared to NVOS's ROE of -1.20%. Regarding short-term risk, SOLV is more volatile compared to NVOS. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.
SOLV vs PIIIW Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, PIIIW has a market cap of 33.3K. Regarding current trading prices, SOLV is priced at $74.59, while PIIIW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas PIIIW's P/E ratio is -0.01. In terms of profitability, SOLV's ROE is +0.12%, compared to PIIIW's ROE of -1.29%. Regarding short-term risk, SOLV is less volatile compared to PIIIW. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs TVTY Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, TVTY has a market cap of 0. Regarding current trading prices, SOLV is priced at $74.59, while TVTY trades at $32.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas TVTY's P/E ratio is 19.06. In terms of profitability, SOLV's ROE is +0.12%, compared to TVTY's ROE of +1.75%. Regarding short-term risk, SOLV is more volatile compared to TVTY. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.
SOLV vs TLMDW Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, TLMDW has a market cap of 0. Regarding current trading prices, SOLV is priced at $74.59, while TLMDW trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas TLMDW's P/E ratio is N/A. In terms of profitability, SOLV's ROE is +0.12%, compared to TLMDW's ROE of -0.46%. Regarding short-term risk, SOLV is less volatile compared to TLMDW. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs NFH Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, NFH has a market cap of 0. Regarding current trading prices, SOLV is priced at $74.59, while NFH trades at $11.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas NFH's P/E ratio is -19.75. In terms of profitability, SOLV's ROE is +0.12%, compared to NFH's ROE of -0.06%. Regarding short-term risk, SOLV is more volatile compared to NFH. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.
SOLV vs TLMD Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, TLMD has a market cap of 0. Regarding current trading prices, SOLV is priced at $74.59, while TLMD trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas TLMD's P/E ratio is -1.60. In terms of profitability, SOLV's ROE is +0.12%, compared to TLMD's ROE of -0.46%. Regarding short-term risk, SOLV is more volatile compared to TLMD. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.
SOLV vs SLHG Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, SLHG has a market cap of 0. Regarding current trading prices, SOLV is priced at $74.59, while SLHG trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas SLHG's P/E ratio is -1.48. In terms of profitability, SOLV's ROE is +0.12%, compared to SLHG's ROE of N/A. Regarding short-term risk, SOLV is less volatile compared to SLHG. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.
SOLV vs DVCR Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, DVCR has a market cap of 0. Regarding current trading prices, SOLV is priced at $74.59, while DVCR trades at $10.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas DVCR's P/E ratio is 28.34. In terms of profitability, SOLV's ROE is +0.12%, compared to DVCR's ROE of -0.15%. Regarding short-term risk, SOLV is more volatile compared to DVCR. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.
SOLV vs HNGR Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, HNGR has a market cap of 0. Regarding current trading prices, SOLV is priced at $74.59, while HNGR trades at $18.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas HNGR's P/E ratio is 19.71. In terms of profitability, SOLV's ROE is +0.12%, compared to HNGR's ROE of +0.52%. Regarding short-term risk, SOLV is more volatile compared to HNGR. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.
SOLV vs SLHGP Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, SLHGP has a market cap of 0. Regarding current trading prices, SOLV is priced at $74.59, while SLHGP trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas SLHGP's P/E ratio is -30.38. In terms of profitability, SOLV's ROE is +0.12%, compared to SLHGP's ROE of -0.71%. Regarding short-term risk, SOLV is more volatile compared to SLHGP. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.
SOLV vs DCGOW Comparison
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 12.9B. In comparison, DCGOW has a market cap of 0. Regarding current trading prices, SOLV is priced at $74.59, while DCGOW trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 34.38, whereas DCGOW's P/E ratio is N/A. In terms of profitability, SOLV's ROE is +0.12%, compared to DCGOW's ROE of -0.00%. Regarding short-term risk, SOLV is less volatile compared to DCGOW. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.